0000899243-22-034069.txt : 20221024
0000899243-22-034069.hdr.sgml : 20221024
20221024185804
ACCESSION NUMBER: 0000899243-22-034069
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221020
FILED AS OF DATE: 20221024
DATE AS OF CHANGE: 20221024
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wheadon David E.
CENTRAL INDEX KEY: 0001789507
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 221326884
MAIL ADDRESS:
STREET 1: C/O ASSERTIO THERAPEUTICS, INC.
STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 835 INDUSTRIAL ROAD
STREET 2: SUITE 600
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 835 INDUSTRIAL ROAD
STREET 2: SUITE 600
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-20
1
0001340652
ChemoCentryx, Inc.
CCXI
0001789507
Wheadon David E.
C/O CHEMOCENTRYX, INC.
835 INDUSTRIAL ROAD, SUITE 600
SAN CARLOS
CA
94070
1
0
0
0
Restricted Stock Unit
2022-10-20
4
D
0
22274
D
Common Stock
22274
0
D
Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash,
(Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2022-10-20